Revolutionizing drug delivery with nanobodies
Currently, nanobodies have shown potential for enhancing drug delivery systems. In our latest research, nanobodies targeting EGFR, mCherry, and HER2 have been found to be effective in directing extracellular vesicles toward specific target cells.
Nanobodies have emerged as a promising tool for drug delivery systems. These small antibody fragments have several advantages over traditional antibodies, including their high stability, small size, and excellent tissue-penetrating properties. These features make them ideal for use in targeted drug delivery systems, where they can be used to deliver drugs directly to specific cells or tissues in the body.
In recent years, researchers have made significant progress in developing nanobodies that can be used to drive extracellular vesicles (EVs) toward specific target cells. EVs are small membrane-bound particles that are released by cells and play a critical role in intercellular communication. By loading EVs with nanobodies that target specific cells or tissues, researchers can create a highly targeted drug delivery system that can deliver drugs directly to the desired location in the body.
Several nanobodies have been identified that are particularly effective at driving EVs toward specific target cells. For example, nanobodies targeting the epidermal growth factor receptor (EGFR), mCherry, or human epidermal growth factor receptor 2 (HER2) have been shown to be highly effective at directing EVs to target cells. These nanobodies can be used to deliver a wide range of drugs, including chemotherapeutic agents, peptides, and nucleic acids, to specific cells or tissues, improving drug efficacy and reducing side effects.
At Jotbody, we’re committed to advancing the field of nanobody research and development, including the use of nanobodies in drug delivery systems. Our team of experts is constantly working to identify new nanobodies that can be used to drive EVs toward specific target cells, and we’re excited about the potential of this technology to improve drug delivery and patient outcomes.
If you’re interested in learning more about the potential of nanobodies in drug delivery systems, please don’t hesitate to contact us. Our team of experts is standing by to answer your questions and help you find the right solution for your research and development needs.
Read more at: https://pubmed.ncbi.nlm.nih.gov/33643546/